$EXEL and $PFE drugs face off in kidney cancer https://t.co/jEXms3mwNV
Exelixis' Cabometyx bests Pfizer's Sutent in advanced renal cell carcinoma study https://t.co/pSF9cGmEFz $EXEL $PFE #ESMO16
RT @fwpharma: Exelixis' Cabometyx bests Pfizer's Sutent in advanced renal cell carcinoma study https://t.co/pSF9cGmEFz $EXEL $PFE #ESMO16
RT @fwpharma: Exelixis' Cabometyx bests Pfizer's Sutent in advanced renal cell carcinoma study https://t.co/pSF9cGmEFz $EXEL $PFE #ESMO16
#Exelixis unveils phase 1 trial results for cabozantinib in combination with nivolumab in a... Read more: https://t.co/2FvjtbIC2M $EXEL
#Exelixis unveils phase 1 trial results for cabozantinib in combination with nivolumab in a... Read more: https://t.co/ur41zJkhrv $EXEL
RT @odibro: $EXEL Announces Positive Results from P2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Advanced #RCC #ESMO16 https://t.co/…
#Exelixis unveils phase 1 trial results for cabozantinib in combination with nivolumab in a... Read more: https://t.co/R0MOP9pMmK $EXEL
Ipsen and Its Partner #Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cab... Read more: https://t.co/RBMttgffBp $EXEL
Ipsen and Its Partner #Exelixis Announce Positive Results from Phase 2 CABOSUN Trial of Cab... Read more: https://t.co/manbq19Y2s $EXEL
#Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Suni... Read more: https://t.co/1zoiK7XpA7 $EXEL
#Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Suni... Read more: https://t.co/Unk0kDSrxb $EXEL
BRIEF-#Exelixis announces positive results from phase 2 trial of Cabozantinib vs Sunitinib. Read more: https://t.co/TX1rhJHF78 $EXEL
RT @Liquid_Biopsy_: $Exel #esmo16 LR ESMO Weekend Prezos Highlight Cabo and Cotellic Potential; CABOSUN Data Monday • Bottom (cont) https:/…
#Exelixis unveils phase 1 trial results for cabozantinib in combination with nivolumab in a... Read more: https://t.co/RoFkcJHxdv $EXEL
#Exelixis unveils phase 1 trial results for cabozantinib in combination with nivolumab in a... Read more: https://t.co/UgJR6OjXBM $EXEL
RT @ohadhammer: @GalOphir $EXEL's data is still very impressive no doubt esp given the extremely low PFS with Sutent and confounding effect…
#Exelixis unveils phase 1 trial results for cabozantinib in combination with nivolumab in a... Read more: https://t.co/n9TtnWwzE3 $EXEL
@ohadhammer @GalOphir why no movement premarket $exel
@GalOphir $EXEL's data is still very impressive no doubt esp given the extremely low PFS with Sutent and confounding effect of subsequent Tx
Early News & Update https://t.co/94u0KZfie1 $NICE $EXEL $FSLR $CPN $EBAY
$EXEL:
Exelixis (EXEL) Announces Statistically Significant Data from …:
https://t.co/58HS4aCNXt
RT @Liquid_Biopsy_: $Exel #esmo16 LR ESMO Weekend Prezos Highlight Cabo and Cotellic Potential; CABOSUN Data Monday • Bottom (cont) https:/…
RT @bio_clouseau: $EXEL Duration of TX in Sunitinib arm much lower than Cabo despite = discontinuation rate and lower dose reduction https:…
RT @Liquid_Biopsy_: $Exel #esmo16 LR ESMO Weekend Prezos Highlight Cabo and Cotellic Potential; CABOSUN Data Monday • Bottom (cont) https:/…
RT @asclepiacap: $EXEL Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib vs Sunitinib in 1L RCC #ESMO16 https://t.co/U…
RT @GalOphir: Eisai's LENVIMA+everolimus combo was FDA approved for 1L RCC with OS=25.5m. $EXEL has OS=30.3m for a mono'. FDA approval very…
RT @Super1NYC: #Premarket Top % Gainers: $IPCI 39%, $MYL 12%, $TSRO 10%, $EXEL 8%, $LPCN 6%, $JNUG 5%, $EXK $NUGT $AG $UWTI $MRK $AUY $SDRL…
RT @Super1NYC: #Premarket Top % Gainers: $IPCI 39%, $MYL 12%, $TSRO 10%, $EXEL 8%, $LPCN 6%, $JNUG 5%, $EXK $NUGT $AG $UWTI $MRK $AUY $SDRL…
#Premarket Top % Gainers: $IPCI 39%, $MYL 12%, $TSRO 10%, $EXEL 8%, $LPCN 6%, $JNUG 5%, $EXK $NUGT $AG $UWTI $MRK $AUY $SDRL $DGAZ $TSLA
RT @odibro: $EXEL Announces Positive Results from P2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Advanced #RCC #ESMO16 https://t.co/…
RT @BiotechGems: 4 Takeover Targets in the Market’s Hottest Sector https://t.co/GbFpPkNByB $EXEL $SGYP $SNY $INCY https://t.co/fbyUoKNndj
4 Takeover Targets in the Market’s Hottest Sector https://t.co/GbFpPkNByB $EXEL $SGYP $SNY $INCY https://t.co/fbyUoKNndj
RT @ohadhammer: @GalOphir $EXEL's data is still very impressive no doubt esp given the extremely low PFS with Sutent and confounding effect…
$EXEL Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously..https://t.co/YiTtwFyBTZ
RT @GalOphir: Eisai's LENVIMA+everolimus combo was FDA approved for 1L RCC with OS=25.5m. $EXEL has OS=30.3m for a mono'. FDA approval very…
$CLSD $TSLA $CRM
$IPCI $MYL $ENZ $TSRO $RGSE $EXEL $MZOR
$IONS $LPCN $CLDX $MRK $SDRL $EXK $AUPH
pre-market top bu… https://t.co/MYVqTjX9gI
$EXEL $PFE:
Exelixis’ Cometriq beats Pfizer’s Sutent in mid-stage kidney cancer …:
https://t.co/Oy7AIYQZtO
Exelixis' Cometriq beats Pfizer's Sutent in mid-stage kidney cancer study; shares up 8% premarket $EXEL $PFE https://t.co/6Vw1FTBy74
Exelixis' Cometriq beats Pfizer's Sutent in mid-stage kidney cancer study; shares up 8% pre... https://t.co/oJ6Fm2Zgin #premarket $EXEL $PFE
Exelixis' Cometriq beats Pfizer's Sutent in mid-stage kidney cancer study; shares up 8% pre... https://t.co/bK27bsmGKM #premarket $EXEL $PFE
Exelixis' Cometriq beats Pfizer's Sutent in mid-stage kidney cancer study; shares up 8% pre... https://t.co/QVFRiH6Sa8 #premarket $EXEL $PFE
Premarket Biotech Digest: $EXEL Reports Encouraging Results, $MYL Rallies, $BMY’s… https://t.co/coS1zHWt9E https://t.co/IWcjE1ocDk
#Premarket Top % Gainers: $IPCI 38%, $TSRO 14%, $MYL 12%, $MZOR $NAVB $LPCN $AUPH $CLDX $MDGS $SDRL $USLV $EXEL $JNUG $UWTI $MGT $EXK $MRK
RT @Super1NYC: #Premarket Top % Gainers: $IPCI 38%, $TSRO 14%, $MYL 12%, $MZOR $NAVB $LPCN $AUPH $CLDX $MDGS $SDRL $USLV $EXEL $JNUG $UWTI…
Premarket Top % Gainers: $IPCI 38%, $TSRO 14%, $MYL 12%, $MZOR $NAVB $LPCN $AUPH $CLDX $MDGS $SDRL $USLV $EXEL $JNUG $UWTI $MGT $EXK $MRK
#Premarket Top % Gainers: $IPCI 38%, $TSRO 14%, $MYL 12%, $MZOR $NAVB $LPCN $AUPH $CLDX $MDGS $SDRL $USLV $EXEL $JNUG $UWTI $MGT $EXK $MRK
Exelixis' Cometriq beats Pfizer's Sutent in mid-stage kidney cancer study; shares up 8% premarket $EXEL $PFE https://t.co/URneWor7BW
$EXEL: Exelixis and Ipsen (IPSEY) report Phase 2 study of Cabozantinib met the primary endpoint of improving... https://t.co/Cj8vZsSv4Z
$EXEL $PFE:
Exelixis’ Cabometyx beats Pfizer’s Sutent in mid-stage kidney cancer …:
https://t.co/RSMxQ4kSLV
Exelixis' Cabometyx beats Pfizer's Sutent in mid-stage kidney cancer study; shares up 8% pr... https://t.co/Q023PWCuqX #premarket $EXEL $PFE
Exelixis' Cabometyx beats Pfizer's Sutent in mid-stage kidney cancer study; shares up 8% pr... https://t.co/kbIyg9vbmE #premarket $EXEL $PFE
Exelixis' Cabometyx beats Pfizer's Sutent in mid-stage kidney cancer study; shares up 8% pr... https://t.co/1QnUZbCwrC #premarket $EXEL $PFE
RT @IcemanTrading: Premarket Top % Gainers: $IPCI 38%, $TSRO 14%, $MYL 12%, $MZOR $NAVB $LPCN $AUPH $CLDX $MDGS $SDRL $USLV $EXEL $JNUG $UW…
RT @Super1NYC: #Premarket Top % Gainers: $IPCI 38%, $TSRO 14%, $MYL 12%, $MZOR $NAVB $LPCN $AUPH $CLDX $MDGS $SDRL $USLV $EXEL $JNUG $UWTI…
#ESMO16 Movers: $TSRO +14% $EXEL +5% $MRK +3% $ARIA +1% $NVS -1% $CLVS -2% $BMY -6%. Biotech ETFs: $IBB +1% $XBI +1%
A few stocks I’m watching this fine Monday morning: $CLDX $EXEL $FTR $IPCI $LPCN $MCUR $MOBL $NTNX $SDRL
RT @danwardbio: #ESMO16 Movers: $TSRO +14% $EXEL +5% $MRK +3% $ARIA +1% $NVS -1% $CLVS -2% $BMY -6%. Biotech ETFs: $IBB +1% $XBI +1%
Premarket most active stocks: $MYL, $AAPL, $XIV, $TVIX, $QQQ, $EXEL, $TSRO, $TSLA, $SQQQ, $TLT
Why These Stocks Are Up https://t.co/UvEeoaKeix $GOOG $AEO $ATHN $CLDX $DE $DOW $EBAY $EXEL $FB $EGAS $IPCI $IONS $MAT
$rnn reports efficacy data - buyout! $gsk $mrk $jnj $gs $alxn $bmy $kerx #Zika #ZikaVirus $wfc $exas $exel
RT @odibro: $EXEL upgraded to Overweight at Piper. PT raised to $21 from $8
$EXEL upgraded to Overweight at Piper. PT raised to $21 from $8
Other positive PM Movers
$SRPT $MRK $VRX $GWPH $IBB $EBIO $CEMP $MCUR $IONS $EXEL$GILD
RT @CBOE: UPSIDE pre-mkt: $EGA, $TSRO, $MYL, $MZOR, $IONS, $EXEL, $WLL, $AEO, $CRM, $MRK powered by https://t.co/scoWUQ48H7 https://t.co/rg…
UPSIDE pre-mkt: $EGA, $TSRO, $MYL, $MZOR, $IONS, $EXEL, $WLL, $AEO, $CRM, $MRK powered by https://t.co/scoWUQ48H7 https://t.co/rgF1pS2m3f
RT @markflowchatter: $EXEL: Upgrade to Overweight at Piper, tgt to $21